Fortis Healthcare Q4 FY26 Results Analysis: PAT Surges 44.6%, EBITDA Margin Expands 214 bps

Fortis Healthcare Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 2,364.67 Cr (+17.84% YoY) and PAT growth of +44.58% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Consolidated revenue grew 17.8% YoY, PAT surged 44.6% YoY, and FY26 EBITDA margin expanded 214 bps to 23.40% from operating leverage. Diagnostics margin nearly doubled, but finance costs rose 70% from acquisition debt and occupancy remains below target, with key legal overhang pending September 2026.

Key Investment Insights

Key Positives

• Consolidated PAT attributable to owners grew 44.58% YoY to Rs.26,585 Lakh in Q4 FY26.
• FY26 EBITDA margin expanded 214 bps to 23.40%, driven by total expenses growing slower than revenue.
• Diagnostics segment EBIT margin expanded 649 bps YoY to 15.84% in FY26.
• Healthcare segment EBIT grew 30.13% YoY in FY26 to Rs.139,370 Lakh with margin expansion of 180 bps.
• Operating cash flow was 150% of PAT, indicating high earnings quality.
• Credit rating upgraded by CRISIL from AA to AA+ (Stable).

Risk Factors

• Occupancy declined to 67% in Q3 FY26 due to new facility ramp-up; Q4 occupancy data not disclosed.
• Current ratio at 0.86x indicates working capital pressure from rapid expansion.
• Tax disputes total Rs.266 Cr (demands for AY 2021-22 and AY 2024-25); company evaluating appeals.
• Legal uncertainty from NTK vs Daiichi Sankyo judgment due September 10, 2026.